Literature DB >> 16919351

Effect of controlled delivery of neurotrophin-3 from fibrin on spinal cord injury in a long term model.

Sara J Taylor1, Shelly E Sakiyama-Elbert.   

Abstract

The goal of this work was to assess the effect of the controlled delivery of neurotrophin-3 (NT-3) from an affinity-based delivery system in fibrin scaffolds on regeneration following spinal cord injury (SCI). A heparin-based delivery system (HBDS) was used to immobilize NT-3 within fibrin scaffolds via non-covalent interactions. The fibrin scaffolds were implanted in lesions immediately after injury in an adult rat model of SCI (complete ablation of a 2 mm segment of the cord at T9). Delivery of NT-3 was controlled by an affinity-based delivery system that limits drug loss by diffusion and releases the drug via cell-mediated processes. Twelve weeks after injury and treatment, animals treated with fibrin scaffolds and NT-3, with or without the delivery system, did not show functional improvement over saline controls. Substantial cavitation at edges of the lesion was present, and while neuronal fibers were present inside the lesion, traced corticospinal and dorsal sensory tracts did not regenerate into the lesion. Therefore, while previous studies indicate that the controlled delivery of NT-3 from fibrin scaffolds may increase the short term regenerative response, the continued degeneration of the cord, indicative of the severity of the injury, limits the long term regeneration stimulated by this treatment. Chronic or repeated treatments or a less severe injury model may prove useful in assessing the utility of controlled delivery systems for the treatment of spinal cord injury.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16919351      PMCID: PMC1855256          DOI: 10.1016/j.jconrel.2006.07.005

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  18 in total

1.  Incorporation of heparin-binding peptides into fibrin gels enhances neurite extension: an example of designer matrices in tissue engineering.

Authors:  S E Sakiyama; J C Schense; J A Hubbell
Journal:  FASEB J       Date:  1999-12       Impact factor: 5.191

2.  Delayed transplantation of fibroblasts genetically modified to secrete BDNF and NT-3 into a spinal cord injury site is associated with limited recovery of function.

Authors:  J S Shumsky; C A Tobias; M Tumolo; W D Long; S F Giszter; M Murray
Journal:  Exp Neurol       Date:  2003-11       Impact factor: 5.330

3.  Cross-linking exogenous bifunctional peptides into fibrin gels with factor XIIIa.

Authors:  J C Schense; J A Hubbell
Journal:  Bioconjug Chem       Date:  1999 Jan-Feb       Impact factor: 4.774

4.  Axonal regeneration and functional recovery after complete spinal cord transection in rats by delayed treatment with transplants and neurotrophins.

Authors:  J V Coumans; T T Lin; H N Dai; L MacArthur; M McAtee; C Nash; B S Bregman
Journal:  J Neurosci       Date:  2001-12-01       Impact factor: 6.167

5.  A sensitive and reliable locomotor rating scale for open field testing in rats.

Authors:  D M Basso; M S Beattie; J C Bresnahan
Journal:  J Neurotrauma       Date:  1995-02       Impact factor: 5.269

6.  Factor XIII-mediated cross-linking of NH2-terminal peptide of alpha 2-plasmin inhibitor to fibrin.

Authors:  A Ichinose; T Tamaki; N Aoki
Journal:  FEBS Lett       Date:  1983-03-21       Impact factor: 4.124

7.  Controlled release of nerve growth factor from a heparin-containing fibrin-based cell ingrowth matrix.

Authors:  S E Sakiyama-Elbert; J A Hubbell
Journal:  J Control Release       Date:  2000-10-03       Impact factor: 9.776

8.  Development of fibrin derivatives for controlled release of heparin-binding growth factors.

Authors:  S E Sakiyama-Elbert; J A Hubbell
Journal:  J Control Release       Date:  2000-04-03       Impact factor: 9.776

9.  NT-3 gene delivery elicits growth of chronically injured corticospinal axons and modestly improves functional deficits after chronic scar resection.

Authors:  Mark H Tuszynski; Ray Grill; Leonard L Jones; Adam Brant; Armin Blesch; Karin Löw; Steve Lacroix; Paul Lu
Journal:  Exp Neurol       Date:  2003-05       Impact factor: 5.330

10.  Heparin binding domain peptides of antithrombin III: analysis by isothermal titration calorimetry and circular dichroism spectroscopy.

Authors:  R Tyler-Cross; M Sobel; D Marques; R B Harris
Journal:  Protein Sci       Date:  1994-04       Impact factor: 6.725

View more
  31 in total

1.  Fibrin degradation enhances vascular smooth muscle cell proliferation and matrix deposition in fibrin-based tissue constructs fabricated in vitro.

Authors:  Katherine A Ahmann; Justin S Weinbaum; Sandra L Johnson; Robert T Tranquillo
Journal:  Tissue Eng Part A       Date:  2010-10       Impact factor: 3.845

2.  Tissue-engineered fibrin scaffolds containing neural progenitors enhance functional recovery in a subacute model of SCI.

Authors:  Philip J Johnson; Alexander Tatara; Dylan A McCreedy; Alicia Shiu; Shelly E Sakiyama-Elbert
Journal:  Soft Matter       Date:  2010-10-21       Impact factor: 3.679

Review 3.  Approaches to neural tissue engineering using scaffolds for drug delivery.

Authors:  Stephanie M Willerth; Shelly E Sakiyama-Elbert
Journal:  Adv Drug Deliv Rev       Date:  2007-04-10       Impact factor: 15.470

Review 4.  Fibrin gels and their clinical and bioengineering applications.

Authors:  Paul A Janmey; Jessamine P Winer; John W Weisel
Journal:  J R Soc Interface       Date:  2009-01-06       Impact factor: 4.118

Review 5.  Biomaterial design strategies for the treatment of spinal cord injuries.

Authors:  Karin S Straley; Cheryl Wong Po Foo; Sarah C Heilshorn
Journal:  J Neurotrauma       Date:  2010-01       Impact factor: 5.269

Review 6.  Biomaterials for Enhancing CNS Repair.

Authors:  Teck Chuan Lim; Myron Spector
Journal:  Transl Stroke Res       Date:  2016-06-01       Impact factor: 6.829

7.  Controlled release of neurotrophin-3 from fibrin-based tissue engineering scaffolds enhances neural fiber sprouting following subacute spinal cord injury.

Authors:  Philip J Johnson; Stanley R Parker; Shelly E Sakiyama-Elbert
Journal:  Biotechnol Bioeng       Date:  2009-12-15       Impact factor: 4.530

8.  The effect of controlled growth factor delivery on embryonic stem cell differentiation inside fibrin scaffolds.

Authors:  Stephanie M Willerth; Allison Rader; Shelly E Sakiyama-Elbert
Journal:  Stem Cell Res       Date:  2008-06-10       Impact factor: 2.020

Review 9.  Cell therapy for spinal cord regeneration.

Authors:  Stephanie M Willerth; Shelly E Sakiyama-Elbert
Journal:  Adv Drug Deliv Rev       Date:  2007-10-05       Impact factor: 15.470

10.  Inhibitor of PI3K/Akt Signaling Pathway Small Molecule Promotes Motor Neuron Differentiation of Human Endometrial Stem Cells Cultured on Electrospun Biocomposite Polycaprolactone/Collagen Scaffolds.

Authors:  Somayeh Ebrahimi-Barough; Elham Hoveizi; Meysam Yazdankhah; Jafar Ai; Mehrdad Khakbiz; Faezeh Faghihi; Roksana Tajerian; Neda Bayat
Journal:  Mol Neurobiol       Date:  2016-03-18       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.